Reaxys, Syngene sign multi-year contract to enhance R&D competitiveness and productivity

Elsevier, the world's leading publisher of scientific content and online solutions announced today that Syngene, India's first contract research organization, has signed a multi-year contract that will provide unlimited access to Reaxys for all Syngene researchers. Reaxys will help Syngene enhance its R&D competitiveness and productivity in the ever-expanding and highly competitive Indian pharmaceutical, chemical and agrochemical research environments.

Dr. Manoj Nerurkar, Head of Small Molecule Discovery & Development at Syngene, said of the agreement, "It's critical for our scientists to have immediate access to the relevant chemical information. We have to generate maximum output with a minimum number of experiments. The insights Reaxys gives us into possible synthetic routes and validated physical property data is crucial in ensuring that when we start in the lab we will generate better output in less time. Starting with Reaxys, we can be sure that the information is reliable and we will not be led down any false routes."

Syngene is already a preferred research service provider to leading players in global pharmaceutical and chemical industries who continue to invest and commit to enlarging their R&D activities in India. Access to Reaxys' validated, curated chemical information will be a key factor in helping Syngene maintain this position.

"Reaxys is dedicated to providing the relevant information that will enable researchers to innovate effectively: to act immediately on their findings from Reaxys and apply them directly in the lab," said Mark van Mierle, Managing Director, Pharma and Biotech Group, Elsevier. "We are pleased to extend our relationship with Syngene and we look forward to continuing to support it in its ongoing R&D efforts."

SOURCE Elsevier